Direct Oral Anticoagulants-Pharmacology, Drug Interactions, and Side Effects

Seminars in Hematology

Volumn 51, Issue 2, 2014, Pages 89-97

  Dempfle, Carl Erik ^a  

^a IMD Coagulation Center Mannheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DRUG METABOLITE; EDOXABAN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN;

ABSENCE OF SIDE EFFECTS; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG MEGADOSE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG USE; FOOD DRUG INTERACTION; HUMAN; KIDNEY CLEARANCE; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; PHARMACOLOGY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DRUG INTERACTIONS; DRUG MONITORING; HALF-LIFE; HEMORRHAGE; HUMANS; KIDNEY; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; THROMBOEMBOLISM;

EID: 84901374763     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.03.005     Document Type: Article

References (72)

1. Sanford M., Plosker G.L. Dabigatran etexilate. Drugs 2008, 68:1699-1709.
2. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013, 34:1498-1505.
3. Keating G.M. Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Drugs 2013, 73:825-843.
4. Levy J.H., Faraoni D., Spring J.L., Douketis J.D., Samama C.M. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013, 118:1466-1474.
5. Krauel K., Hackbarth C., Furll B., Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012, 119:1248-1255.
6. Wienen W., Stassen J.M., Priepke H., Ries U.J., Hauel N. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 2007, 5:1237-1242.
7. Hauel N.H., Nar H., Priepke H., Ries U., Stassen J.M., Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002, 45:1757-1766.
8. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-295.
9. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
10. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
11. Stangier J., Rathgen K., Stahle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64:292-303.
12. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
13. Stangier J., Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009, 15(Suppl 1):9S-16S.
14. Stangier J., Eriksson B.I., Dahl O.E., et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005, 45:555-563.
15. van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
16. Eriksson B.I., Quinlan D.J., Weitz J.I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009, 48:1-22.
17. Liesenfeld K.H., Lehr T., Dansirikul C., Reilly P.A., Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011, 9:2168-2175.
18. Dansirikul C., Lehr T., Liesenfeld K.H., Haertter S., Staab A. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012, 107:775-785.
19. Stangier J., Stahle H., Rathgen K., Roth W., Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008, 48:1411-1419.
20. Stangier J., Stahle H., Rathgen K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008, 47:47-59.
21. Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011, 31:326-343.
22. Dans A.L., Connolly S.J., Wallentin L., Yang S., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013, 127:634-640.
23. Clemens A., Haertter S., Friedman J., Brueckmann M., Stangier J., van Ryn J., Lehr T. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012, 28:195-201.
24. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23:138-143.
25. Huisman M.V., Lip G.Y., Diener H.C., Brueckmann M., van Ryn J., Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012, 107.
26. Perzborn E., Strassburger J., Wilmen A., Pohlmann J., Roehrig S., Schlemmer K.H., Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3:514-521.
27. Turpie A.G., Lassen M.R., Eriksson B.I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011, 105:444-453.
28. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
29. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
30. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
31. Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., Kakkar A.K., et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007, 116:180-187.
32. Buller H.R., Lensing A.W., Prins M.H., Agnelli G., Cohen A., Gallus A.S., Misselwitz F., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112:2242-2247.
33. Mueck W., Borris L.C., Dahl O.E., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-461.
34. Mueck W., Lensing A.W., Agnelli G., Decousus H., Prandoni P., Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
35. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
36. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol 2006, 46:981-990.
37. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
38. Mueck W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor--in healthy subjects. Int J. Clin Pharmacol Ther 2007, 45:335-344.
39. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46:549-558.
40. Graff J., von Hentig N., Misselwitz F., Kubitza D., Becka M., Breddin H.K., Harder S. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007, 47:1398-1407.
41. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007, 47:218-226.
42. Gheorghiade M., Thyssen A., Zolynas R., et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant 2011, 30:218-226.
43. Kubitza D., Becka M., Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
44. Kubitza D., Becka M., Roth A., Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24:2757-2765.
45. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007, 63:469-476.
46. Jiang X., Crain E.J., Luettgen J.M., Schumacher W.A., Wong P.C. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009, 101:780-782.
47. Luettgen J.M., Knabb R.M., He K., Pinto D.J., Rendina A.R. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem 2011, 26:514-526.
48. Frost C., Nepal S., Wang J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013, 76:776-786.
49. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
50. Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-2375.
51. Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
52. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
53. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
54. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
55. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
56. Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
57. Upreti V.V., Wang J., Barrett Y.C., et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013, 76:908-916.
58. Wang L., Zhang D., Raghavan N., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010, 38:448-458.
59. Camm A.J., Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs 2011, 71:1503-1526.
60. Ogata K., Mendell-Harary J., Tachibana M., Masumoto H., Oguma T., Kojima M., Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50:743-753.
61. Kuroda Y., Hirayama C., Hotoda H., Nishikawa Y., Nishiwaki A. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag 2013, 9:593-598.
62. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369:1406-1415.
63. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
64. Mendell J., Tachibana M., Shi M., Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011, 51:687-694.
65. Bathala M.S., Masumoto H., Oguma T., He L., Lowrie C., Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012, 40:2250-2255.
66. Salazar D.E., Mendell J., Kastrissios H., et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012, 107:925-936.
67. Mendell J., Zahir H., Matsushima N., et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013, 13:331-342.
68. Mendell J., Lee F., Chen S., Worland V., Shi M., Samama M.M. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol 2013, 62:212-221.
69. Mendell J., Noveck R.J., Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 2012, 60:335-341.
70. Charbonnier B.A., Fiessinger J.N., Banga J.D., Wenzel E., D'Azemar P., Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost 1998, 79:897-901.
71. Hillarp A., Baghaei F., Fagerberg Blixter I., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9:133-139.
72. Lindahl T.L., Baghaei F., Blixter I.F., et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105:371-378.